Recognising and Managing DOAC Complications
Direct Oral Anticoagulants (DOACs) are increasingly prescribed for the prevention and treatment of thromboembolic disorders, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, despite their convenience over traditional vitamin K antagonists (VKAs), DOACs present specific complications that healthcare professionals must recognize and manage to ensure patient safety. This course provides in-depth knowledge on how to identify and manage DOAC-related complications such as bleeding, thrombosis, and renal dysfunction. Participants will explore the pharmacology of DOACs, including the differences between available agents like rivaroxaban, apixaban, dabigatran, and edoxaban. The course covers common adverse effects and the mechanisms behind them, as well as strategies for managing overdose, bleeding, and drug interactions.
.jpg)
Learning Outcomes
What you'll learn
- Recognize the complications associated with DOAC therapy, including bleeding and thromboembolic events.
- Understand the pharmacology of DOACs and the differences between agents such as rivaroxaban, apixaban, dabigatran, and edoxaban.
- Effectively monitor and manage bleeding complications, including appropriate use of reversal agents.
- Address renal dysfunction and drug interactions in patients taking DOACs.
- Apply evidence-based strategies for managing DOAC overdose and patient-specific risks.
- Educate patients on the potential risks and benefits of DOAC therapy, as well as the signs and symptoms of complications.


Learning Outcomes
What you'll learn
- Recognize the complications associated with DOAC therapy, including bleeding and thromboembolic events.
- Understand the pharmacology of DOACs and the differences between agents such as rivaroxaban, apixaban, dabigatran, and edoxaban.
- Effectively monitor and manage bleeding complications, including appropriate use of reversal agents.
- Address renal dysfunction and drug interactions in patients taking DOACs.
- Apply evidence-based strategies for managing DOAC overdose and patient-specific risks.
- Educate patients on the potential risks and benefits of DOAC therapy, as well as the signs and symptoms of complications.


Modules
- Introduction to DOACs – Pharmacology and Mechanisms of Action
- Identifying and Managing Bleeding Complications
- Thrombosis in DOAC Therapy – Recognizing and Managing Clotting Events
- Monitoring Renal Function in DOAC Therapy
- Drug Interactions with DOACs
- Patient Education and Adherence to DOAC Therapy
- Summary
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Top reviews
No reviews yet.
You May Also Like
Come and Work
with Us!
Join us as a healthcare trainer providing practical sessions to professionals and workers.
Apply for Trainer RoleIn-Person Practical
Healthcare Training
Enroll in our accredited, hands-on practical training sessions to deliver better patientcentred care.
Apply for TrainingRefer &
Earn Rewards.
Invite healthcare professionals to join Care Learning and earn rewards for every successful referral.
Frequently Asked Questions
The most common complications of DOAC therapy include bleeding, thrombosis, and drug interactions. Management includes dose adjustment, monitoring renal function, and using reversal agents when needed.
Bleeding in patients on DOACs can be managed by discontinuing the drug, administering reversal agents (such as andexanet alfa for Factor Xa inhibitors), and providing supportive measures like blood transfusions if necessary.
Renal function should be monitored regularly, especially in elderly patients or those with pre-existing kidney disease, as impaired renal function increases the risk of bleeding complications.
No, DOACs are contraindicated in patients with severe hepatic disease, especially those with hepatic impairment that leads to coagulopathy, as these patients may not be able to safely metabolize the drugs.
If a patient develops thrombosis despite being on DOAC therapy, therapy should be reassessed, possibly switching to other anticoagulants such as LMWH or warfarin.
Drug interactions can either increase the anticoagulant effect of DOACs (leading to bleeding) or reduce their effectiveness (leading to thrombosis).
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)